Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | BIRC8 | Q96P09 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638262 | 0.86 | NPY1R (0.39) | NPY1RXIAPMMP1MMP3MME | |
| SCHEMBL5637870 | 0.84 | EPHX1 (0.40) | NPY1RMMP1MMP3MMEACE | |
| SCHEMBL5638966 | 0.82 | ALDH1A1 (0.36) | NPY1RXIAPMMP1MMP3MME | |
| SCHEMBL5638607 | 0.82 | KMT2A (0.38) | XIAPMMEACE | |
| SCHEMBL5638791 | 0.82 | XIAP (0.33) | NPY1RXIAPMMP1MMP3 | |
| SCHEMBL5638785 | 0.82 | NPY1R (0.33) | NPY1RXIAPMMP1MMP3 | |
| SCHEMBL5637810 | 0.82 | LMNA (0.40) | MMEACE | |
| SCHEMBL5639951 | 0.81 | MEN1 (0.37) | NPY1RXIAPMMP1MMP3MME | |
| SCHEMBL5639334 | 0.80 | ALDH1A1 (0.39) | MMP1MMP3MMEACE | |
| SCHEMBL5638919 | 0.79 | ALDH1A1 (0.36) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | NPY1R 265/4885XIAP 2106/4885MMP1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.